Finch Therapeutics Group, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Finch Therapeutics continues to pursue intellectual property monetization after ceasing clinical development, reporting a net loss of $4.834 million for the quarter ended June 30, 2024, but also securing a favorable jury verdict in a patent infringement case.
Finch Therapeutics continues its strategic shift towards realizing the value of its intellectual property, reporting a net loss of $3.876 million for Q1 2024.